Anatoliy N. Samko

Anatoliy N. Samko

Auto-generated profile, based on publicly available information

Anatoliy N. Samko

National Medical Research Center of Cardiology

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1999 in International Journal of Cardiology
Verified
Journal Article
Closed access
VFViorel G Florea
Viorel G Florea
VMVyaceslav Yu Mareyev
Vyaceslav Yu Mareyev
ASAnatoli N Samko
Anatoli N Samko
IOIana Orlova
Iana Orlova
ACAndrew J.S Coats
Andrew J.S Coats
YBYuri N Belenkov
Yuri N Belenkov

14 August 2012 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YSYulia Andreevna Shuvalova
Yulia Andreevna Shuvalova
AKA. I. Kaminnyi
A. I. Kaminnyi
Alexey MeshkovAlexey Meshkov
Alexey Meshkov
RSR. O. Shirokov
R. O. Shirokov
ASA. N. Samko
A. N. Samko

1 January 2002 in Platelets
Verified
Journal Article
Closed access
AMA.V. Mazurov
A.V. Mazurov
DPD.V. Pevzner
D.V. Pevzner
OAO.A. Antonova
O.A. Antonova
Tatiana V. ByzovaTatiana V. Byzova
Tatiana V. Byzova
SKS.G. Khaspekova
S.G. Khaspekova
MRM.Ya. Ruda
M.Ya. Ruda
The purpose of the study was to evaluate safety, effects on platelet aggregation and pharmacokinetics of F(ab') 2 fragments of anti-glycoprotein (GP) IIb-IIIa murine monoclonal antibody FRaMon (F(ab') 2 FRaMon) upon its intravenous administration in patients undergoing high-risk coronary angioplasty. Patients were treated before angioplasty with F(ab') 2 FRaMon at 0.2 mg/kg ( n = 17) and 0.25 mg/kg ( n = 12) bolus or with abciximab at 0.25 mg/kg bolus + 12 h infusion at 0.125 w g/kg per min ( n = 29). F(ab') 2 FRaMon at both doses decreased platelet aggregation induced by 20 w M ADP to 95, 70-80 and 40-50% of GP IIb-IIIa at 1 and 12-24 h and 3 days after injection, respectively. Thrombotic complications within the first month after angioplasty in groups treated with F(ab') 2 FRaMon and abciximab were observed in one and two patients, respectively. The data obtained have shown that F(ab') 2 FRaMon at bolus administration to patients undergoing coronary angioplasty caused no serious side effects and at comparative dosage inhibited platelet aggregation with the same efficacy as abciximab at bolus + infusion administration.

16 April 2018 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
TKT. G. Kulikova
T. G. Kulikova
OSO. V. Stepanova
O. V. Stepanova
AVA. D. Voronova
A. D. Voronova
MVM. P. Valikhov
M. P. Valikhov
VSV. N. Sirotkin
V. N. Sirotkin
GSG. T. Sukhikh
G. T. Sukhikh

30 October 2001 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Open access
PDF file
TATatiana Arefieva
Tatiana Arefieva
SPSergey I Provatorov
Sergey I Provatorov
ASAnatoly N Samko
Anatoly N Samko
TKTatiana L Krasnikova
Tatiana L Krasnikova
TRTherese J Resink
Therese J Resink
ECEugeniy I Chazov
Eugeniy I Chazov
SUMMARY: 1. In the present study, we sought to determine whether patients with restenosis after coronary stenting possess increased monocyte reactivity, as manifested by a higher level of adhesion molecule expression and an enhanced propensity to form monocyte–platelet aggregates after activation in vitro.2. Anti‐coagulated peripheral venous blood from 24 patients, 10 with and 14 without angiographically verified restenosis, was obtained. Leucocyte antigen expression and the number of leucocyte–platelet complexes were measured by flow cytometry after activation in whole blood.3. Surface integrin Mac‐1 (CD11b/CD18) and VLA‐4 (CD49d/ CD29) expression on monocytes and the relative number of monocyte–platelet complexes after in vitro activation were significantly elevated in patients with restenosis compared with patients without restenosis (fluorescence intensities of 1425 ± 76 vs 1195 ± 71, 87 ± 7 vs 65 ± 6 and 47 ± 4 vs 29 ± 3% for for Mac‐1, VLA‐4 and monocyte–platelet complexes, respectively; P < 0.05 for each parameter).4. The results suggest that restenosis is associated with increased monocyte VLA‐4 and Mac‐1 integrin expression and monocyte–platelet complex formation, which can be revealed after activation in vitro.

1 August 1991 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
MSM. Samsonov
M. Samsonov
ENE. Nassonov
E. Nassonov
SKS. Kostin
S. Kostin
ASA. Samko
A. Samko
LAL. Alexandrova
L. Alexandrova
VZV. Zhdanov
V. Zhdanov
Measurement of neopterin in biological fluids is a sensitive and specific tool for detecting activation of the T cell/macrophage system. Serum neopterin level, detected by radioimmunoassay, and data from morphological investigations of myocardium were compared in 29 patients with a clinical diagnosis of dilated heart muscle disease. According to the results of endomyocardial biopsy (22 cases) and autopsy (seven cases), 14 patients had morphological features of myocarditis, 13 dilated cardiomyopathy and two a fibrotic subtype of dilated cardiomyopathy (DCMP). The mean neopterin level in all patients (12±9nM−1) was higher than in the control group (5±2nm−1) (P<07middot;05). Also, the mean neopterin level was significantly higher in patients with myocarditis and fibrotic subtype of DCMP (16±11 nM l−1) than in patients with a morphological diagnosis of DCMP (9±6nM l−1) (P<0·05). The highest neopterin levels in both groups were found in those who subsequently died during follow-up (mean level 23±10nM l−1). There was a correlation between neopterin and β2-microglobulin (r = 0·83, P<0·05). Our study suggests that the raised serum neopterin level may be a marker of myocardial inflammation and unfavourable prognosis in patients with a clinical diagnosis of dilated heart muscle disease.